-
41.发明申请公开(公告)号：US20190119652A1
公开(公告)日：2019-04-25
申请号：US16093361
申请日：2017-04-12
申请人： NSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP) , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , INSTITUT PASTEUR , UNIVERSITÉ PARIS XIII PARIS-NORD
IPC分类号： C12N7/00 , A61K35/76 , C07K14/005 , A61P31/00
摘要： The present invention relates to a bacteriophage strain capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone. The burden of STl31-025b:H4 Escherichia coli clonal complex in human community and hospital-acquired infections is increasing worldwide, going along with a worrying and growing resistance to betalactams and fluoroquinolones. Bacteriophage LM33_P1 infects exclusively (100% specificity) 025b E. coli strains with 70% coverage on the two major antibiotic resistant pandemic clonal complexes STI31-025b:H4 and ST69-025b. The inventors evaluated the in vivo activity of bacteriophage LM33_P1 using three different extraintestinal virulence murine models and showed that it infects bacteria in several organs. In particular, the invention relates to a bacteriophage capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone comprising a polypeptide corresponding to the bacteriophage tail fiber protein and responsible for the attachment of the bacteriophage to the Escherichia coli ST131-025b:H4 clone.
-
42.发明申请公开(公告)号：US20180296474A1
公开(公告)日：2018-10-18
申请号：US15765854
申请日：2016-10-12
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , UNIVERSITÉ PARIS DESCARTES , SORBONNE UNIVERSITE , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , FONDATION ASILE DES AVEUGLES
IPC分类号： A61K9/00 , A61P27/02 , A61K31/551
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion. In particular, the present invention relates to a method of treating retinal capillary non-perfusion in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a ROCK inhibitor.
-
公开(公告)号：US20180153507A1
公开(公告)日：2018-06-07
申请号：US15580026
申请日：2016-06-09
申请人： Institut National de la Sante et de la Recherche Medicale (INSERM) , Centre national de la recherche scientifique , Université Pierre et Marie Curie (Paris 6) , Université Paris Diderot - Paris 7 , ECOLE SUPERIEURE DE PHYSIQUE ET DE CHIME INDUSTRIELLES DE LA VILLE DE PARIS
IPC分类号： A61B8/00 , A61B5/0478 , A61B5/11 , A61B8/06
CPC分类号： A61B8/4416 , A61B5/04001 , A61B5/0478 , A61B5/11 , A61B5/1118 , A61B8/06 , A61B8/0808 , A61B8/4209 , A61B8/481 , A61B8/488 , A61B2503/40 , A61B2562/0209 , A61B2562/0219 , A61B2562/066 , A61B2562/166
摘要： The invention concerns a detecting apparatus (12) comprising:—at least two sensors (24, 26, 28), with at least one sensor (24) being an ultrasound transducer adapted to produce ultrasound waves, and—a positioning device (16) defining several compartments (22), each compartment (22) being adapted to hold a sensor (24, 26, 28) and each compartment (22) being located at predetermined location, the positioning device (16) comprising a holder adapted to be fixed on the skull of a subject, the positioning device (16) being adapted to be maintained on the head of the subject using the holder.
-
44.发明申请公开(公告)号：US20180057819A1
公开(公告)日：2018-03-01
申请号：US15809541
申请日：2017-11-10
申请人： Centre National de la Recherche Scientifique-CNRS , INSERM ( Institut National de la Sante et de la Recherche Medicale , URGO RECHERCHE INNOVATION ET DEVELOPPEMENT , Université Paris Diderot-Paris 7 , Ecole Normale Superieure
IPC分类号： C12N15/113 , C07K14/47 , A61K45/06 , A61K31/713
CPC分类号： C12N15/113 , A61K31/713 , A61K45/06 , A61K2300/00 , C07K14/4702 , C12N2310/14 , C12N2320/12 , C12N2320/30
摘要： The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of HIC1, FOXS1, CREB5, IRF7, POU2F2, STAT4, TCF4, and/or an agent that enhances the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2.
-
45.发明授权公开(公告)号：US09879090B2
公开(公告)日：2018-01-30
申请号：US14772339
申请日：2014-03-04
申请人： Institut National De La Santé Et De La Recherche Médicale (Inserm) , Université Paris Diderot - Paris 7 , Universite Des Antilles Et De La Guyane , Institut National De La Transfusion Sanguine (INTS)
发明人： Olivier Bertrand , Ibrahim Habib , Dorota Smolarek
CPC分类号： C07K16/34 , A61K38/162 , A61K47/64 , A61K47/6849 , C07K14/005 , C07K16/2896 , C07K2317/21 , C07K2317/22 , C07K2317/34 , C07K2317/569 , C07K2317/92 , C07K2317/94 , C07K2319/00 , C12N7/00 , C12N2740/16022 , C12N2740/16033 , G01N33/86 , G01N2333/70596
摘要： The present invention relates to isolated VHHs directed against human Glycophorin A. The present invention also relates to fusion proteins comprising the VHH according to the invention that is fused to at least one heterologous polypeptide and immunoconjugates comprising the VHH according to the invention that is conjugated to at least one chemical compound and their use in therapeutic or diagnostic methods.
-
公开(公告)号：US20170281628A1
公开(公告)日：2017-10-05
申请号：US14909669
申请日：2014-07-30
申请人： URGO RECHERCHE INNOVATION ET DÉVELOPPEMENT , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE- CNRS , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , ECOLE NORMALE SUPERIEURE
IPC分类号： A61K31/519 , C12N15/113 , A61L15/16 , A61K31/506 , A61K45/06 , A61K9/00 , A61K31/197
CPC分类号： A61K31/519 , A61K9/0014 , A61K31/197 , A61K31/506 , A61K45/06 , A61L15/16 , A61L2300/432 , C07K14/4702 , C12N15/113 , C12N2310/14
摘要： The present invention relates to a therapeutic compound comprising: an agent that inhibits the activity of at least one gene selected from the group consisting of MAF, MEOX2, SIX2 and homologues thereof having at least 50% identity with said genes and/or an agent that enhances the activity of at least one gene selected from the group consisting of CREBS, E2F1, EGR2, HIC1, IRF7, JUN, MYC, SRF, STAT4, TCF4, FOXS1, GLI1, SOX9 and homologues thereof having at least 50% identity with said gene for use in the treatment of wounds, preferably chronic wounds.
-
47.发明申请公开(公告)号：US20170247450A1
公开(公告)日：2017-08-31
申请号：US15514173
申请日：2015-09-18
CPC分类号： C07K16/28 , A61K39/0005 , A61K39/3955 , A61K2039/505 , A61K2039/575 , C07K16/2863 , C07K2317/24 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/92 , C07K2317/94
摘要： The present invention relates to an anti-Notch 3 antibody therapy useful for treatment of patients with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy. In particular, the invention relates to an anti-Notch3 antibody or a fragment thereof having a 2 fold, 4 fold or 10 fold higher affinity to Notch 3 than to Notch 1 or Notch 2 for use in therapy.
-
公开(公告)号：US20170239242A1
公开(公告)日：2017-08-24
申请号：US15512872
申请日：2015-09-21
申请人： INSERM(INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
发明人： Sophie LOTERSZTAJN , Aïda HABIB
IPC分类号： A61K31/496 , A61K31/4525
CPC分类号： A61K31/496 , A61K31/4015 , A61K31/4525 , A61K31/4535 , A61K31/454 , A61K31/4545
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of fibrosis. In particular, the present invention relates to a method of treating fibrosis in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one monoacylglycerol lipase (MGL) inhibitor.
-
49.发明申请公开(公告)号：US20170202925A1
公开(公告)日：2017-07-20
申请号：US15320827
申请日：2015-06-23
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , ASSISTANCE PUBLIQUE -HÔPITAUX DE PARIS
CPC分类号： A61K38/22 , A61K45/06 , A61K2300/00
摘要： The present invention relates to methods and pharmaceutical compositions for the treatment of inflammatory bowel diseases. The presents methods relates to a method of treating an inflammatory bowel disease in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one OX1R agonist.
-
公开(公告)号：US20170130267A1
公开(公告)日：2017-05-11
申请号：US15125355
申请日：2015-03-17
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PARIS DIDEROT - PARIS 7 , UNIVERSITÉ PARIS DESCARTES , ASSISTANCE PUBLIQUE-HÔPITAUX DE PARIS (APHP)
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/158 , C12Q2600/178
摘要： The present invention relates to method for predicting acute rejection in heart recipients. In particular, the present invention relates to a method for predicting acute rejection in a heart recipient comprising the steps consisting of i) determining the expression level (ELi) of at least one miRNAi selected from the group consisting of miR-155, miR-10a, miR-92a and miR-31 in a blood sample obtained from the heart recipient, ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) and iii) and concluding that the recipient has a high risk of developing acute rejection when the level the expression level (ELi) determined at step i) is different (higher or lower) than the predetermined reference level (ELRi).
-
-
-
-
-
-
-
-
-
搜索结果
86 条记录 (耗时 0.028 秒)
